Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer

Bilal A. Siddiqui, Sumit K. Subudhi, Padmanee Sharma

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemistry